

Juan JosÃ© Perez-Ruixo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2342202/publications.pdf>

Version: 2024-02-01

114
papers

3,652
citations

186265

28
h-index

144013

57
g-index

119
all docs

119
docs citations

119
times ranked

3930
citing authors

#	ARTICLE	IF	CITATIONS
1	Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 569-580.	2.5	7
2	Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 151-164.	2.3	5
3	Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 119-128.	2.4	9
4	Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. <i>Clinical Pharmacokinetics</i> , 2021, 60, 501-516.	3.5	26
5	A quantitative systems pharmacology model for acute viral hepatitis B. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4997-5007.	4.1	1
6	Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1239-1250.	3.5	5
7	An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1227-1237.	3.5	5
8	A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1605-1619.	3.5	2
9	Delay differential equations based models in NONMEM. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 763-802.	1.8	4
10	Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 826-838.	2.5	0
11	Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00846.	2.4	2
12	Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. <i>Clinical Pharmacokinetics</i> , 2021, 60, 541-561.	3.5	3
13	Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects. <i>Clinical Pharmacokinetics</i> , 2020, 59, 229-244.	3.5	12
14	Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 238-245.	4.7	6
15	Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 515-527.	2.0	7
16	Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4460-4467.	7.0	12
17	Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome. <i>Clinical and Translational Science</i> , 2020, 13, 807-817.	3.1	8
18	Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens. <i>AAPS Journal</i> , 2020, 22, 30.	4.4	4

#	ARTICLE	IF	CITATIONS
19	Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF. <i>Pharmaceutical Research</i> , 2020, 37, 102.	3.5	4
20	Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposureâ€“QTc in patients with advanced or refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 621-633.	2.3	4
21	Population pharmacokinetics of trabectedin in adolescent patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 707-717.	2.3	2
22	Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. <i>Clinical Drug Investigation</i> , 2019, 39, 1223-1232.	2.2	3
23	Immune network for viral hepatitis B: Topological representation. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104939.	4.0	1
24	Hematopoietic Growth Factors. , 2019, , 521-535.		2
25	A Receiver Operating Characteristic Framework for Non-adherence Detection Using Drug Concentration Thresholdsâ€“Application to Simulated Risperidone Data in Schizophrenic Patients. <i>AAPS Journal</i> , 2019, 21, 40.	4.4	4
26	Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. <i>AAPS Journal</i> , 2019, 21, 1.	4.4	27
27	Pharmacokineticâ€“pharmacodynamic modelling of neutrophil response to Gâ€“CSF in healthy subjects and patients with chemotherapyâ€“induced neutropenia. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 911-925.	2.4	20
28	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018, 57, 529-538.	3.5	24
29	Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach. <i>AAPS Journal</i> , 2018, 20, 111.	4.4	0
30	Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 771-779.	2.5	5
31	Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 721-724.	4.7	57
32	Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 87-109.	2.5	261
33	Pharmacodynamic Model of Hcpidin Regulation of Iron Homeostasis in Cynomolgus Monkeys. <i>AAPS Journal</i> , 2016, 18, 713-727.	4.4	7
34	Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 484-494.	2.5	15
35	A cell-level model of pharmacodynamics-mediated drug disposition. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 513-527.	1.8	4
36	Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. <i>AAPS Journal</i> , 2016, 18, 239-250.	4.4	4

#	ARTICLE	IF	CITATIONS
37	Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S85-92.	2.0	4
38	Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1157-1166.	2.0	5
39	Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 620-628.	2.0	26
40	Rilotumumab Exposure-Response Relationship in Patients with Advanced or Metastatic Gastric Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2453-2461.	7.0	32
41	Development and Validation of an HPLC-UV Method for Pazopanib Quantification in Human Plasma and Application to Patients With Cancer in Routine Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 172-179.	2.0	12
42	Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 709-720.	1.8	4
43	Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 333-347.	1.8	10
44	Population pharmacokinetics of kahalalide F in advanced cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 365-374.	2.3	17
45	A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 315-332.	1.8	11
46	Pharmacokinetic and Pharmacodynamic Relationship of AMG 811, An Anti-IFN- γ IgG1 Monoclonal Antibody, in Patients with Systemic Lupus Erythematosus. <i>Pharmaceutical Research</i> , 2015, 32, 640-653.	3.5	34
47	Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis. <i>Blood</i> , 2015, 126, 4222-4222.	1.4	17
48	Similar Relationship Between the Time Course of Bone Mineral Density Improvement and Vertebral Fracture Risk Reduction With Denosumab Treatment in Postmenopausal Osteoporosis and Prostate Cancer Patients on Androgen Deprivation Therapy. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 503-512.	2.0	6
49	Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 328-336.	3.3	19
50	Development and Validation of an HPLC-UV Method for Sorafenib Quantification in Human Plasma and Application to Patients With Cancer in Routine Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 317-325.	2.0	14
51	Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 291-318.	1.8	30
52	Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1009-1020.	2.3	6
53	Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response-Based Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3746-3755.	3.6	47
54	Translational Modeling to Identify Human Dosing of Filgrastim to Improve Overall Survival (OS) in Acute Radiation Syndrome (ARS). <i>Blood</i> , 2014, 124, 690-690.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals. <i>Pharmaceutical Research</i> , 2013, 30, 655-669.	3.5	27
56	The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics. <i>AAPS Journal</i> , 2013, 15, 172-182.	4.4	29
57	Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 693-704.	2.3	10
58	Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1063-1083.	3.5	16
59	Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1111-1125.	3.5	9
60	Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 15-25.	2.4	8
61	The Use of Pharmacometrics to Optimize Biosimilar Development. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3908-3914.	3.3	8
62	Development and Validation of a High-Performance Liquid Chromatography Ultraviolet Method for Lapatinib Quantification in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 796-802.	2.0	15
63	Romiplostim dose-response in patients with myelodysplastic syndromes. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1445-1454.	2.4	7
64	Hematopoietic Growth Factors: Focus on Erythropoiesis-Stimulating Agents. , 2013, , 361-374.		0
65	Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2648-2657.	7.0	27
66	Romiplostim Dose Response in Patients With Immune Thrombocytopenia. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1540-1551.	2.0	12
67	Population Pharmacokinetic-Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®). <i>Clinical Pharmacokinetics</i> , 2012, 51, 751-764.	3.5	13
68	Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours. <i>Clinical Pharmacokinetics</i> , 2012, 51, 247-260.	3.5	72
69	Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 15-24.	2.3	17
70	Lifespan based indirect response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 109-123.	1.8	16
71	Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Erythropoietic Stimulating Agents. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , 307-323.	0.6	1
72	Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis. <i>Clinical Pharmacokinetics</i> , 2011, 50, 793-807.	3.5	90

#	ARTICLE	IF	CITATIONS
73	Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 978-981.	2.4	14
74	Pharmacokinetic and Pharmacodynamic Analysis of Hyperthermic Intraperitoneal Oxaliplatin-Induced Neutropenia in Subjects with Peritoneal Carcinomatosis. <i>AAPS Journal</i> , 2011, 13, 72-82.	4.4	14
75	Immunogenicity of panitumumab in combination chemotherapy clinical trials. <i>BMC Clinical Pharmacology</i> , 2011, 11, 17.	2.5	23
76	Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Heparin in Cynomolgus Monkeys. <i>AAPS Journal</i> , 2010, 12, 646-657.	4.4	74
77	Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects. <i>AAPS Journal</i> , 2010, 12, 729-740.	4.4	68
78	Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies. <i>Clinical and Translational Oncology</i> , 2010, 12, 437-442.	2.4	27
79	Modeling the Effectiveness of Paliperidone ER and Olanzapine in Schizophrenia: Meta-Analysis of 3 Randomized, Controlled Clinical Trials. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 293-310.	2.0	12
80	Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab. <i>Clinical Pharmacokinetics</i> , 2010, 49, 729-740.	3.5	63
81	Exposure-Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 75S-90S.	2.0	21
82	Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG-TPOm) After Single Intravenous Dose Administration in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 336-350.	2.0	30
83	Semi-Mechanistic Model for Neutropenia after High Dose of Chemotherapy in Breast Cancer Patients. <i>Pharmaceutical Research</i> , 2009, 26, 1952-1962.	3.5	14
84	Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 97-108.	2.3	27
85	Pharmacokinetics of erythropoiesis-stimulating agents. , 2009, , 199-223.		1
86	Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetic Body Construct CNTO 528 in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2009, 48, 601-613.	3.5	35
87	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 327-335.	2.5	60
88	Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 349-377.	1.8	29
89	Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 135-147.	2.3	28
90	Mechanism-based Pharmacokinetic/Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 130-143.	4.7	38

#	ARTICLE	IF	CITATIONS
91	Pharmacodynamic Analysis of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2008, 47, 399-415.	3.5	41
92	Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2007, 46, 159-173.	3.5	47
93	Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis) in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 867-884.	3.5	38
94	Exposure-toxicity relationships for tipifarnib in cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 219-232.	2.4	4
95	Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 669-675.	1.9	19
96	An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy Subjects. <i>Pharmaceutical Research</i> , 2007, 24, 758-772.	3.5	29
97	Modeling Methadone Pharmacokinetics in Rats in Presence of P-glycoprotein Inhibitor Valspodar. <i>Pharmaceutical Research</i> , 2007, 24, 1299-1308.	3.5	11
98	Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 81-96.	2.4	30
99	Modelling intestinal absorption of salbutamol sulphate in rats. <i>International Journal of Pharmaceutics</i> , 2006, 314, 21-30.	5.2	4
100	Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 681-691.	2.3	7
101	Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 24, 465-475.	4.0	41
102	A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. <i>Cancer</i> , 2005, 103, 2035-2041.	4.1	52
103	Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients. <i>Journal of Oncology Pharmacy Practice</i> , 2004, 10, 155-167.	0.9	3
104	Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3950-3957.	1.6	232
105	Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1430-1438.	1.6	740
106	Population pharmacokinetic analysis of pegylated human erythropoietin in rats. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 3027-3038.	3.3	25
107	Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks. <i>IEEE Transactions on Biomedical Engineering</i> , 2003, 50, 442-448.	4.2	33
108	Dosage individualization of erythropoietin using a profile-dependent support vector regression. <i>IEEE Transactions on Biomedical Engineering</i> , 2003, 50, 1136-1142.	4.2	49

#	ARTICLE	IF	CITATIONS
109	Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure. Computers in Biology and Medicine, 2003, 33, 361-373.	7.0	32
110	Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2003, 21, 1301-1306.	1.6	164
111	Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer. Journal of Clinical Oncology, 2003, 21, 2492-2499.	1.6	197
112	Cyclosporine concentration prediction using clustering and support vector regression methods. Electronics Letters, 2002, 38, 568.	1.0	12
113	Population pharmacokinetics of cyclosporine in kidney transplant patients. Transplantation Proceedings, 1999, 31, 2246-2247.	0.6	7
114	Simulation in Clinical Drug Development. , 0, , 1-26.		2